Giuseppe Caruso, Gynecology Oncology Specialist at European Institute of Oncology, shared a post a post on LinkedIn:
“Counting lines… or miscounting them?
A welcome clarification for daily practice!
In oncology, we often find ourselves counting prior lines of therapy— determining trial eligibility, sequencing treatments, and aligning with protocols. Yet, in real-world practice, this seemingly simple task is anything but straightforward. How often do we label a treatment change as a new line when it actually isn’t?
The recent ESMO – European Society for Medical Oncology EnLiST consensus framework provides much-needed clarity.
- New LoT: if progression
- Modified LoT: if intolerance, adding an agent, logistic/financial issues
- Same LoT: if change in dose, route, dropping an agent, re-introducing it
Excellent graphical abstract in the first comment!”
Title: ESMO Adaptation of Lines of Systemic Therapy (EnLiST): a consensus framework for standardising the designation of lines of therapy in solid tumours
Authors: K. Saini, M. Koopman, D. Martins-Branco, P. Bossi, S. Braendegaard, M. Brahmi, I. Braña, E. Calvo, L. Castelo-Branco, I. Colombo, E. de Azambuja, D. De Ruysscher, R. Dienstmann, A. Dingemans, M. Ekholm, C. Gallois, V. Golfinopoulos, E. Grande, S. Halabi, E. Le Rhun, O. Le Saux, N. Leighl, S. Lonardi, S. Lorenzen, D. Lorusso, G. Minniti, G. Mountzios, J. Oldenburg, S. Oosting, P. Osterlund, J. Perez-Gracia, A. Pellat, S. Piperno-Neumann, R. Plummer, C. Porta, K. Punie, I. Ray-Coquard, J. Remon, C. Ruhlmann, P. Rutkowski, L. Siu, S. Stacchiotti, C. Suarez, K. Suijkerbuijk, J. Taieb, D. Trapani, A. Valachis, H. van Laarhoven, A. Vogel, A. Zer, G. Pentheroudakis, S. Delaloge, C. Twelves
Read the Full Article.
Other articles featuring Giuseppe Caruso on OncoDaily.
